Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia (AML) characterized by t(15;17)(q24;21) and the fusion gene PML-RARA. With optimal supportive care and frontline use of all-trans retinoic acid (ATRA) and chemotherapy, first complete remission (CR1) rates of more than 90% and long-term survival of more 80% can be achieved. Regimens that include As₂O₃, ATRA and chemotherapy result in a CR rare of 90-100% and OS between 86-97% (1–3). Frontline treatment of APL has evolved rapidly. An emerging theme is the incorporation of As₂O₃ early in the treatment algorithm, starting from induction to consolidation.